THE GIRAFFE Study: Genomic Risk Markers for Atrial Fibrillation Following Extended Cardiac Rhythm Monitoring
NCT ID: NCT01970969
Last Updated: 2018-04-17
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
928 participants
OBSERVATIONAL
2013-09-30
2017-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Identification of Genetic, Biochemical and Hormonal Factors Contributing to Atrial Fibrillation
NCT00599118
Prospective Phenotyping for Genetic Subtypes of Early-onset Atrial Fibrillation
NCT05190679
The Genetic Basis for Atrial Fibrillation
NCT03491202
Gene Expression Profiling in Subjects With Postoperative Atrial Fibrillation After Cardiac Surgery (GENEXPRO Surg)
NCT00833313
Genetic Markers of Coronary Heart Disease in Type 2 Diabetes
NCT00078052
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Cardiac arrhythmia symptoms
All subjects enrolled in the study will have an iRhythm Zio patch placed and a blood sample obtained.
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
AND
* At high risk for atrial fibrillation, defined as any one of the following: ischemic stroke with no defined etiology (In prior 6 months) \[3, 4, 6, 7\], hypertension \[33\], increased body mass index (BMI \>30kg/m2) \[33\], heart failure \[33\], clinically significant murmur \[33\], prolonged PR interval on resting ECG \[33\], chronic kidney disease \[34\], hypertrophic cardiomyopathy \[35\], congenital heart disease \[36\], chronic obstructive pulmonary disease \[37, 38\], sleep apnea \[39-41\], thyroid disease \[42, 43\], family history of atrial fibrillation \[44\], diabetes \[45\] or excess alcohol consumption (Male \> 14 drinks/week, Female \>7 drinks/week)\[46\].
* Age 40 years or older
* Capable of providing informed consent
* Capable of wearing a Zio Patch for up to 14 days
* Capable of providing a blood sample
Exclusion Criteria
* Prior cardiac surgery (coronary artery bypass grafting, valve replacement or repair, pericardial stripping, etc) within the past 30 days.
* Hyperthyroidism.
* Have known skin allergies, conditions, or sensitivities (e.g. allergy to adhesives, psoriasis) as the Zio Patch should not be used on patients with known skin allergies, conditions, or sensitivities.
* Are receiving pacing therapy.
* Are anticipated to receive or require external cardiac defibrillation during the monitoring period.
* Are anticipated to have exposure to high frequency surgical equipment during the monitoring period.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Quest Diagnostics-Nichols Insitute
INDUSTRY
Scripps Translational Science Institute
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Eric Topol, MD
Role: PRINCIPAL_INVESTIGATOR
Scripps Translational Science Institute
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Scripps Clinic
La Jolla, California, United States
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Muse ED, Wineinger NE, Spencer EG, Peters M, Henderson R, Zhang Y, Barrett PM, Rivera SP, Wohlgemuth JG, Devlin JJ, Shiffman D, Topol EJ. Validation of a genetic risk score for atrial fibrillation: A prospective multicenter cohort study. PLoS Med. 2018 Mar 13;15(3):e1002525. doi: 10.1371/journal.pmed.1002525. eCollection 2018 Mar.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
13-6159
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.